GO
Loading...

Enter multiple symbols separated by commas

Pharmaceuticals

More

  • TRENTON, N.J.— Drugmaker Endo International PLC is climbing toward the top of the steadily consolidating generic medicine business with a deal to buy Par Pharmaceutical Holdings Inc. for about $8.05 billion. In the U.S., that includes the biggest health insurers and two pharmacy benefit managers, Express Scripts Holding Co. and CVS Health Corp. In other...

  • Cancer breakthrough targets sugar to enhance treatment: HALO CEO

    Helen Torley, Halozyme Therapeutics CEO, discusses a new drug that is disrupting the way cancer patients are treated.

  • May 14- Drug maker Actavis Plc said its Warner Chilcott unit held talks with U.S. government officials to discuss a potential resolution of an investigation into the unit's sales activities, according to a regulatory filing. Warner Chilcott said the company and several of its employees in the sales organization received subpoenas in 2012 from the United...

  • Ranbaxy filed "grossly inadequate" applications seeking approval for its drugs and deceived the FDA into granting approvals and giving the company market exclusivity, the class action lawsuit asserts. The FDA has banned import of drugs from all of Ranbaxy's India- based plants under a wider scrutiny of the country's $15 billion pharmaceutical industry,...

  • Jim O’Neill thinks we need $2B to fund new drugs Thursday, 14 May 2015 | 11:13 AM ET

    As the list of drug-resistant bacteria grows, more research into new antibiotics is needed, according to ex-Goldman Sachs economist Jim O’Neill, who was also made U.K. Commercial Secretary on Thursday.

  • ASCO's immunotherapies update   Thursday, 14 May 2015 | 6:19 AM ET
    ASCO's immunotherapies update

    CNBC's Meg Tirrell takes a look at new cancer-fighting drugs and other therapies in the pipeline.

  • LONDON, May 14- Companies that develop new antibiotics should be awarded prize money of up to $3.5 billion for each new drug, instead of selling the medication at a profit, a review backed by Britain's government said on Thursday. The review, lead by former Goldman Sachs chief economist Jim O'Neill, said the lump sum payments could add up to $16- $37 billion over 10...

  • Biotech to watch ahead of ASCO   Wednesday, 13 May 2015 | 2:36 PM ET
    Biotech to watch ahead of ASCO

    The American Society of Clinical Oncology conference will occur at the end of May in Chicago. CNBC's Meg Tirrell reports which companies investors should watch. Also, Les Funtleyder, ESquared Asset Management, shares his view.

  • How much do Americans spend on drugs?   Wednesday, 13 May 2015 | 1:52 PM ET
    How much do Americans spend on drugs?

    A new report says the number of Americans being billed more than $100,000 a year for their prescriptions has tripled in the past year. CNBC's Meg Tirrell breaks down the report, saying slightly more than half of the spenders were men.

  • NEW YORK— Shares of the drugmaker Orexigen are under pressure after the Japanese drugmaker Takeda, its partner on the obesity drug Contrave, said it may end its work with Orexigen. Takeda says Orexigen breached an agreement between the companies. Shares of Orexigen fell 92 cents, or 15.6 percent, to $5.01 in afternoon trading.

  • Drug 'super spenders' rack up $52 billion last year   Wednesday, 13 May 2015 | 9:00 AM ET
    Drug 'super spenders' rack up $52 billion last year

    The number of Americans spending more than $100,000 on medicine nearly tripled in 2014 compared to the prior year.

  • Your prescriptions costs what?   Wednesday, 13 May 2015 | 6:44 AM ET
    Your prescriptions costs what?

    CNBC's Meg Tirrell takes a look at the soaring prices of some drugs and what is driving costs higher.

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • NEW YORK— Irish drugmaker Perrigo said Tuesday it bought the Mexican operations of Pantheon Pharmaceuticals, expanding its business in that country and giving it the ability to manufacture drugs in soft gel form. Perrigo said it paid $34 million for the Pantheon business. Perrigo Co. makes over-the-counter medicines, generic drugs, nutritional products and...

  • Moderna Therapeutics No. 1 on Disruptor 50: Here's why

    Moderna Therapeutics' CEO Stephane Bancel discusses the company's discovery of utilizing messenger RNA, which helps to direct the body's own cells to build proteins and fight rare diseases.

  • A hot biotech that may be the next Genentech Tuesday, 12 May 2015 | 7:00 AM ET
    Biotech

    This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.

  • Disruptor 50: No.1 Moderna Therapeutics Tuesday, 12 May 2015 | 7:00 AM ET
    Stéphane Bancel, president and founding CEO, Moderna Therapeutics

    A biotech company that helps the human body make the medicine it needs to cure a range of disease—from cancer to diabetes.

  • Disruptor 50: No. 29 Intarcia Therapeutics Tuesday, 12 May 2015 | 7:00 AM ET
    Kurt Graves, CEO of Intarcia Therapeutics

    Investors believe Intarcia's drug-delivery system could very well upend the $55 billion worldwide market for treating Type-2 diabetes.

  • *Actavis initial forecast historically conservative- analysts. Sales of Allergan products for 15 days and the drugs acquired with the Forest Laboratories deal helped Actavis beat revenue estimate in the quarter ended March 31. Actavis, whose shares were up 3 percent, outbid Canadian drugmaker Valeant Pharmaceuticals International Inc and activist...